Immunotherapy combination extends survival in advanced endometrial cancer

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

Read it at Medical Xpress ↗

← Front page